CD36：慢性肾脏病治疗的新靶点

CD36:a New Therapeutic Target for Chronic Kidney Disease

CD36是一种细胞表面跨膜糖蛋白受体,与配体结合参与机体多种生理病理过程。近年来研究发现CD36在慢性肾脏病(CKD)中表达增加。本文首先介绍了CD36的结构功能及其表达调控,通过总结国内外文献,并结合前期的研究基础,叙述了CD36在CKD发病中的相关作用机制,得出CD36通过介导肾脏脂质沉积、脂质过氧化、肾脏细胞对多种物质的内吞及细胞内/外信号转导,促进CKD的进展。同时指出可溶性CD36作为CKD进展的生物标志物的可行性,并对CKD药物治疗的研发进行了展望,以期为CKD的诊治提供新的方向。

The transmembrane glycoprotein receptor CD36 binds to ligands participating in various physiological and pathological processes in the body.The recent studies found increased expression of CD36 in chronic kidney disease(CKD). To introduce the structure,function and expression regulation of CD36,this article described the related mechanism of CD36 in CKD by summarizing the domestic and foreign literatures as well as previous studies.It came to the conclusions that CD36 promoted the progress of CKD in four aspects that included renal lipid deposition,lipid peroxidation,a variety of material endocytosis and intracellular/external cell signal transduction.At the same time,this article pointed out the feasibility of soluble CD36 as a biomarker for detecting the development of CKD,and prospected for drug therapy of CKD in order to provide a new direction for the diagnosis and treatment of CKD.